FDA's Woodcock on New Unit to Boost Drug Oversight

FDA's Woodcock on New Unit to Boost Drug Oversight Play

Feb. 14 (Bloomberg) -- Janet Woodcock, director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, speaks about the agency's decision to form a new unit to improve the FDA's scrutiny of brand-name, generic and over-the-counter drugs. Woodcock speaks at the Bloomberg 2014 State of Health Care summit in New York. (Source: Bloomberg)

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus